Halozyme's lead drug flops in PhI­II, forc­ing CEO to ax 160 and re­set fo­cus on tech plat­form

4 years ago
R&D

Alzheimer's stun­ner: Chi­nese biotech wins OK for a new drug on pos­i­tive da­ta — and they have some high-pro­file sup­port­ers

4 years ago
China
FDA+

Da­ta sug­gest gene, cell ther­a­py tri­al ini­ti­a­tions in Eu­rope lag be­hind North Amer­i­ca — here's why

4 years ago
R&D
FDA+

Eight years af­ter a land­mark buy­out, Sanofi agrees to pay ag­griev­ed Gen­zyme share­hold­ers $315M to set­tle foot-drag­ging claims

4 years ago
R&D
Pharma

Am­gen takes a $2.7B stake in BeiGene, gain­ing a promi­nent al­ly in Chi­na to help seize a lead­ing role in can­cer drug com­mer­cial­iza­tion and de­vel­op­ment

4 years ago
Deals
China

Sanofi's on­col­o­gy R&D group marks a pair of set­backs on isat­ux­imab/Lib­tayo com­bo as can­cer stud­ies fiz­zle out

4 years ago
R&D

Oz Azam beefs up Tmu­ni­ty's to­tal raise to $231M as they steer to­ward hu­man da­ta in the dri­ve to cell ther­a­py 2.0

4 years ago
R&D

Roche signs up Dicer­na in a $200M-plus cash al­liance to help de­vel­op a hep B cock­tail, cap­ping the biotech's big year

4 years ago
Deals

Pe­ter Hecht’s Iron­wood spin­out fails back-to-back stud­ies on a key drug, crush­ing shares and trig­ger­ing cut­backs — but he still sees a path for­ward

4 years ago
R&D

Am­gen is join­ing the bio­phar­ma ex­o­dus out of neu­ro­sciences R&D, cut­ting 180 R&D jobs in re­or­ga­ni­za­tion

4 years ago
R&D

No­var­tis takes a hit as FDA or­ders a hold on Zol­gens­ma tri­als in wake of fresh safe­ty con­cerns

4 years ago
Pharma
Cell/Gene Tx

FDA ex­perts vote to yank the agen­cy's 2011 OK of con­tro­ver­sial preterm birth drug af­ter a tri­al fail­ure

4 years ago
FDA+

Hey, wait up Am­gen and Mi­rati, Boehringer In­gel­heim is join­ing the KRAS crowd as ear­ly suc­cess in­spires ri­vals

4 years ago
R&D

GSK team clinch­es pos­i­tive tri­al for the first po­ten­tial new TB vac­cine in a cen­tu­ry — with mil­lions of lives at stake

4 years ago
R&D

Mi­rati team demon­strates that their KRAS G12C drug is ac­tive in NSCLC — but how do they stack up next to Am­gen?

4 years ago
R&D

As­traZeneca’s triplet with Imfinzi, treme and chemo works on a key end­point for front­line lung can­cer

4 years ago
R&D

Here’s a new way to raise mon­ey for your biotech. This trail­blaz­er came out $61M ahead with a place on the NYSE

4 years ago
Deals

FDA backs Mike Grey's bet on a come­back drug play with break­through sta­tus for mar­al­ix­i­bat

4 years ago
FDA+

David Hung is back, launch­ing a new on­col­o­gy start­up with $275M and big am­bi­tions to make news in can­cer drug de­vel­op­ment

4 years ago
Financing
Startups

Mixed ear­ly da­ta on Agios' AG-270 sug­gest com­bo ther­a­py could be way for­ward

4 years ago
R&D

A GSK-led con­sor­tium looks to break ground with a new class of an­tibi­ot­ic, push­ing in­to a piv­otal

4 years ago
R&D

Christo­pher Haqq joins Eli­cio to hunt fa­ther's RAS can­cer; Kro­nos ex­pands top team with Gilead, Bay­lor vets

4 years ago
Peer Review

Ab­b­Vie dou­bles down on cys­tic fi­bro­sis R&D, adding a new drug to the pipeline as Ver­tex seals its dom­i­na­tion of the field with Trikaf­ta OK

4 years ago
R&D

Gilead ex­ecs flag tri­al fail­ures for Sjö­gren’s and lu­pus drugs — while swap­ping out a fa­vorite HIV pro­gram of top an­a­lyst

4 years ago
R&D
First page Previous page 178179180181182183184 Next page Last page